1. Home
  2. CUE vs JEQ Comparison

CUE vs JEQ Comparison

Compare CUE & JEQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • JEQ
  • Stock Information
  • Founded
  • CUE 2014
  • JEQ 1990
  • Country
  • CUE United States
  • JEQ United States
  • Employees
  • CUE N/A
  • JEQ N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • JEQ Air Freight/Delivery Services
  • Sector
  • CUE Health Care
  • JEQ Consumer Discretionary
  • Exchange
  • CUE Nasdaq
  • JEQ Nasdaq
  • Market Cap
  • CUE 94.4M
  • JEQ 81.1M
  • IPO Year
  • CUE 2018
  • JEQ N/A
  • Fundamental
  • Price
  • CUE $1.32
  • JEQ $5.79
  • Analyst Decision
  • CUE Strong Buy
  • JEQ
  • Analyst Count
  • CUE 5
  • JEQ 0
  • Target Price
  • CUE $5.00
  • JEQ N/A
  • AVG Volume (30 Days)
  • CUE 195.8K
  • JEQ 32.0K
  • Earning Date
  • CUE 03-10-2025
  • JEQ 01-01-0001
  • Dividend Yield
  • CUE N/A
  • JEQ 7.05%
  • EPS Growth
  • CUE N/A
  • JEQ N/A
  • EPS
  • CUE N/A
  • JEQ N/A
  • Revenue
  • CUE $9,532,000.00
  • JEQ N/A
  • Revenue This Year
  • CUE $73.11
  • JEQ N/A
  • Revenue Next Year
  • CUE $11.02
  • JEQ N/A
  • P/E Ratio
  • CUE N/A
  • JEQ N/A
  • Revenue Growth
  • CUE 149.53
  • JEQ N/A
  • 52 Week Low
  • CUE $0.45
  • JEQ $4.99
  • 52 Week High
  • CUE $2.37
  • JEQ $6.39
  • Technical
  • Relative Strength Index (RSI)
  • CUE 48.32
  • JEQ 43.84
  • Support Level
  • CUE $1.22
  • JEQ $5.81
  • Resistance Level
  • CUE $1.54
  • JEQ $6.05
  • Average True Range (ATR)
  • CUE 0.11
  • JEQ 0.07
  • MACD
  • CUE -0.01
  • JEQ -0.01
  • Stochastic Oscillator
  • CUE 35.29
  • JEQ 31.58

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About JEQ abrdn Japan Equity Fund Inc.

Aberdeen Japan Equity Fund Inc is a United States-based closed-end diversified management investment company. Its investment objective is to outperform over the long term, on a total return basis (including appreciation and dividends), the Tokyo Stock Price Index ("TOPIX"). The fund seeks to achieve its investment objective by investing a majority of its assets, in equity securities of companies listed on the Tokyo Stock Exchange or listed on the over-the-counter market in Japan or listed on other stock exchanges in Japan. The portfolio of investments is spread across Consumer Discretionary, Industrials, Information Technology, Financials, and other sectors.

Share on Social Networks: